2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $107M | $119M | $156M | $142M | $163M |
Cost of Revenue | $69M | $75M | $100M | $91M | $100M |
Gross Profit | $38M | $44M | $56M | $51M | $62M |
Gross Profit % | 36% | 37% | 36% | 36% | 38% |
R&D Expenses | $1.9M | $2.1M | $2.7M | $2.5M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | -$39M | -$3.8M | -$952K | -$3.2M | $8.1M |
Dep. & Amort. | $5.9M | $4.5M | $4.3M | $4.6M | $5.3M |
Def. Tax | -$3.2M | $96K | $266K | $152K | -$380K |
Stock Comp. | $8.5M | $6.6M | $6M | $5.4M | $5.2M |
Chg. in WC | $14M | $2.3M | -$14M | -$4.7M | -$8.9M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $16M | $22M | $16M | $17M | $26M |
ST Investments | $0 | $0 | $0 | $0 | $0 |
Cash & ST Inv. | $16M | $22M | $16M | $17M | $26M |
Receivables | $30M | $29M | $32M | $43M | $37M |
Inventory | $35M | $34M | $37M | $42M | $41M |
NCS Multistage reported a 14% year-over-year revenue growth in 2024, reaching $162.6 million, with international revenue doubling to 10% of total revenue.
Adjusted EBITDA for 2024 was $22.3 million, a significant improvement from $11.9 million in 2023, with free cash flow of $12 million and $10 million after distributions to non-controlling interests.
For Q1 2025, the company expects revenue between $42 million and $46 million, adjusted gross margin of 39-42%, and adjusted EBITDA between $4.5 million and $6.5 million.
Full-year 2025 guidance includes revenue of $165 million to $175 million and adjusted EBITDA of $20 million to $23 million, with free cash flow after distributions projected at $7 million to $10 million.
NCS plans to continue investing in international markets, pursue M&A opportunities for strategic growth, and focus on R&D for new product development to expand into new market segments.